Literature DB >> 19303565

New trends in Clostridium difficile virulence and pathogenesis.

C Denève1, C Janoir, I Poilane, C Fantinato, A Collignon.   

Abstract

The disease spectrum caused by Clostridium difficile infection ranges from antibiotic-associated diarrhoea to life-threatening clinical manifestations such as pseudomembranous colitis. C. difficile infection is precipitated by antimicrobial therapy that causes a disruption of the normal colonic microbiota, predisposing to C. difficile intestinal colonisation. The pathogenicity of C. difficile is mediated by two exotoxins, TcdA and TcdB, both of which damage the human colonic mucosa and are potent cytotoxic enzymes. C. difficile must first be implanted in the gut and attach to epithelial cells, which are protected by a layer of dense mucus. Confirmed and putative accessory virulence factors that could play a role in adherence and intestinal colonisation have been identified and include proteolytic enzymes and adhesins. Recently, the epidemiology of C. difficile infection has radically changed and an increased incidence is associated with outbreaks in North America and Europe. Several reports suggest that disease severity is increasing to include sepsis syndrome and toxin megacolon. Elderly, debilitated patients in hospitals and nursing homes are particularly vulnerable. A hypervirulent, epidemic strain has been associated with the changing epidemiology and severity of disease. Here, we review the characteristics of the epidemic NAP1, PCR ribotype 027 C. difficile strain that could explain its hypervirulence and epidemic spread.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19303565     DOI: 10.1016/S0924-8579(09)70012-3

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  70 in total

1.  Transcriptional profiling of Clostridium difficile and Caco-2 cells during infection.

Authors:  Tavan Janvilisri; Joy Scaria; Yung-Fu Chang
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

Review 2.  [New antibiotics: small or big advances?].

Authors:  R Draenert; J R Bogner
Journal:  Internist (Berl)       Date:  2009-10       Impact factor: 0.743

3.  Pleiotropic role of the RNA chaperone protein Hfq in the human pathogen Clostridium difficile.

Authors:  P Boudry; C Gracia; M Monot; J Caillet; L Saujet; E Hajnsdorf; B Dupuy; I Martin-Verstraete; O Soutourina
Journal:  J Bacteriol       Date:  2014-06-30       Impact factor: 3.490

4.  Role of the global regulator Rex in control of NAD+ -regeneration in Clostridioides (Clostridium) difficile.

Authors:  Laurent Bouillaut; Thomas Dubois; Michael B Francis; Nadine Daou; Marc Monot; Joseph A Sorg; Abraham L Sonenshein; Bruno Dupuy
Journal:  Mol Microbiol       Date:  2019-04-02       Impact factor: 3.501

5.  Statin use and the risk of Clostridium difficile in academic medical centres.

Authors:  Christine Anne Motzkus-Feagans; Amy Pakyz; Ronald Polk; Giovanni Gambassi; Kate L Lapane
Journal:  Gut       Date:  2012-03-22       Impact factor: 23.059

6.  Impact of ribotype 027 on Clostridium difficile infection in a geriatric department.

Authors:  G Mascart; M Delmée; J Van Broeck; E Cytryn; R Karmali; S Cherifi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-05       Impact factor: 3.267

Review 7.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

8.  The (p)ppGpp Synthetase RSH Mediates Stationary-Phase Onset and Antibiotic Stress Survival in Clostridioides difficile.

Authors:  Astha Pokhrel; Asia Poudel; Kory B Castro; Michael J Celestine; Adenrele Oludiran; Alden J Rinehold; Anthony M Resek; Mariam A Mhanna; Erin B Purcell
Journal:  J Bacteriol       Date:  2020-09-08       Impact factor: 3.490

Review 9.  Reducing Clostridium difficile in the Inpatient Setting: A Systematic Review of the Adherence to and Effectiveness of C. difficile Prevention Bundles.

Authors:  Anna K Barker; Caitlyn Ngam; Jackson S Musuuza; Valerie M Vaughn; Nasia Safdar
Journal:  Infect Control Hosp Epidemiol       Date:  2017-03-27       Impact factor: 3.254

10.  The key sigma factor of transition phase, SigH, controls sporulation, metabolism, and virulence factor expression in Clostridium difficile.

Authors:  Laure Saujet; Marc Monot; Bruno Dupuy; Olga Soutourina; Isabelle Martin-Verstraete
Journal:  J Bacteriol       Date:  2011-05-13       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.